1 Product identity

Ingredient risk

No flagged ingredients

Proflavanol C 200

Name: Proflavanol C 200
Brand: USANA

BrandUSANA→Botanical with Nutrients Tablet or Pill 14 ingredients DSLD #240975

Net contents: 28 Tablet(s)

Target: Adults and Children 4 years and above

DSLD entry: 2020-12-26

2 Ingredients (14)

IngredientGroupSafety

Vitamin CVitamin C (mixed ascorbates)—

Grape seed extractGrape —

Microcrystalline CelluloseCellulose—

pregelatinized StarchPregelatinized starch—

Croscarmellose SodiumCroscarmellose Sodium—

Ascorbyl PalmitateVitamin CGenerally Safe

Silicon DioxideSiliconGenerally Safe

DextrinDextrin—

natural Grape flavorGrape —

DextroseGlucose—

Soy Lecithinlecithin—

Sodium CarboxymethylcelluloseCarboxy Methyl Cellulose—

SteviaStevia—

Sodium CitrateSodium Citrate—

Ingredient amounts require the full DSLD label. View full label at NIH DSLD →

3 Safety cross-reference

Vitamin C — Limited Evidence

⚠ GI distress at high doses

⚠ Kidney stones risk >1g/day

Grape Seed Extract — Limited Evidence

⚠ Antiplatelet effect

⚠ May interact with anticoagulants

Sodium — Limited Evidence

⚠ Hypertension

⚠ Fluid retention

Silicon — Generally Safe

⚠ Very low toxicity

4 Label claims

• All Other

5 Data source

DSLD ID240975

Full labelView at NIH DSLD →

SourceOffice of Dietary Supplements, NIH

Market statusOn market

Entry date2020-12-26

6 More from USANA

View USANA Safety Scorecard → 7 products

Active Calcium BabyCare Prenatal Chelated Mineral BabyCare Prenatal Mega Antioxidant EstroPro Mega Antioxidant Poly C

7 Cite this page

Vancouver

Pkhakadze G. Proflavanol C 200 — product analysis [Internet]. Tbilisi: Public Health Institute of Georgia; 2026 [cited 2026 Aug 27]. Available from: https://supplement.ge/products/dsld-240975/

CC BY 4.0. Product data from NIH DSLD; safety analysis by SupplementIndex.

Analyzed by SupplementIndex

PHIG · Editor-in-Chief: Prof. Giorgi Pkhakadze, MD, MPH, PhD

Product data sourced from the NIH Dietary Supplement Label Database (DSLD). Safety cross-referencing by SupplementIndex. This analysis is for informational purposes only. For corrections: info@accreditation.ge.
Publisher: PHIG